Cinacalcet in the management of primary hyperparathyroidism

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 1, 2012, Pages 45-53

  Cetani, Filomena ^a   Marcocci, Claudio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

calcium sensing receptor; hypercalcemia; parathyroid carcinoma; persistent primary hyperparathyroidism

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE;

ARTHRALGIA; ARTICLE; CALCIUM BLOOD LEVEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; MULTIPLE ENDOCRINE NEOPLASIA; MYALGIA; NAUSEA; NEPHROLITHIASIS; NONHUMAN; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 82955239787     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.84     Document Type: Article

References (46)

1. Melton LJ 3rd. Epidemiology of primary hyperparathyroidism. J. Bone Miner. Res. 6(Suppl. 2), S25-S30 (1991).
2. Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121(3), 287-294 (1997).
3. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 351-365 (2009).
4. Silverberg SJ, BilezikianJP. Primary hyperparathyroidism. In: Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism (7th Edition). Rosen CJ (Ed.). Sheridan Press, PA, USA, 302-306 (2008).
5. Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann. Surg. 223(3), 402-412 (1995).
6. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyrodism: proceedings of the Third International Workshop. J. Clin. Endocrinol. Metab. 94(2), 373-381 (2009).
7. Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the Type 2 calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308(2), 627-635 (2004).
8. Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol. Metab. 10(2), 66-71 (1999).
9. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl Acad. Sci. USA 95(7), 4040-4045 (1998).
10. Messa P, Alfieri C, Brezzi B. Clinical utilization of cinacalcet in hypercalcemic conditions. Exp. Opin. Drug Metab. Toxicol. 7(4), 217-228 (2011).
11. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 67(2), 467-476 (2005).
12. Kawata T, Imanishi Y, Kobayashi K et al. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur. J. Endocrinol. 153(4), 587-594 (2005).
13. Ohashi N, Uematsu T, Nagashima S et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br. J. Clin. Pharmacol. 57(6), 726-734 (2004).
14. Kumar GN, Sproul C, Poppe L et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab. Dispos. 32(12), 1491-1500 (2004).
15. Padhi D, Salfi M, Harris RZ. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. Am. J. Ther. 14(3), 235-240 (2007).
16. Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin. Ther. 27(11), 1725-1751 (2005).
17. Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin. Pharmacokinet. 46(6), 495-501 (2007).
18. Padhi D, Harris RZ, Salfi M, Sullivan JT. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/ Mimpara). Clin. Pharmacokinet. 44(5), 509-516 (2005).
19. Padhi D, Salfi M, Emery M. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents: a randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D 9(5), 335-343 (2008).
20. Padhi D, Harris RZ, Salfi M, Noveck RJ, Sullivan JT. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment: Phase 1, open-label, parallel-group, single-dose, single-centre study. Clin. Drug Invest. 28(10), 635-643 (2008).
21. Nakashima D, Takama H, Ogasawara Y et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J. Clin. Pharmacol. 47(10), 1311-1319 (2007).
22. Silverberg SJ, Bone HG 3rd, Marriott TB et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med. 337(21), 1506-1510 (1997).
23. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 88(12), 5644-5649 (2003).
24. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90(1), 135-141 (2005).
25. Peacock M, Bolognese MA, Borofsky M et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J. Clin. Endocrinol. Metab. 94(12), 4860-4867 (2009).
26. Peacock M, Bilezikian JP, Bolognese MA et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J. Clin. Endocrinol. Metab. 96(1), E9-E18 (2011).
27. Cetani F, Saponaro F, Banti C et al. Cinacalcet efficacy in patients with moderately severe pimary hyperparathyroidism according to the European Medicine Agency prescription labeling. J. Endocrinol. Invest. doi:10.3275/7970 (2011) (Epub ahead of print).
28. Dvorak MM, Chen TH, Orwoll B et al. Constitutive activity of the osteoblast Ca2+-sensing receptor promotes loss of cancellous bone. Endocrinology 148(7), 3156-3163 (2007).
29. Vezzoli G, Terranegra A, Arcidiacono T et al. R990G polymorphism of calcium sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int. 71(11), 1155-1162 (2007).
30. Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet. Genom. 15(1), 29-34 (2005).
31. Rothe HM, Shapiro WB, Sun WY, Matalon A. Calcium-sensing receptor gene polymorphism Arg990Gly a influences the response to calcimimetic agents in end-stage kidney disease patients with secondary hyperparathyroidism. Pers. Med. 5(2), 109-116 (2008).
32. Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 140(6), 874-881 (2006).
33. Horjus C, Groot I, Telting D et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J. Pediatr. Endocrinol. Metab. 22(8), 741-749 (2009).
34. Akinci B, Comlekci A, Tankurt E. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. Exp. Clin. Endocrinol. Diabet. 117(3), 142-145 (2009).
35. Fanari Z, Kadikoy H, Haque W, Pacha O, Abdellatif A. Medical management of primary hyperparathyroidism with concomitant multiple myeloma. Inter. Med. 49(6), 581-584 (2010).
36. Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am. J. Kidney Dis. 48(5), 832-837 (2006).
37. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroidcarcinoma. J. Bone Miner. Res. 23(12), 1869-1880 (2008).
38. Silverberg SJ, Faiman C, Bilezikian JP et al. The effect of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTx. J. Bone Miner. Res. 18(Suppl. 2), S171 (Abstract SA 420) (2003).
39. Silverberg SJ, Rubin MR, Faiman C et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J. Clin. Endocrinol. Metab. 92(10), 3803-3808 (2007).
40. Marcocci C, Chanson P, Shoback D et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94(8), 2766-2772 (2009).
41. Falchetti A, Cilotti A, Vaggelli L et al. A patient with MEN1-associate hyperparathyroidism, responsive to cinacalcet. Nat. Clin. Pract. Endocrinol. Metab. 4(6), 351-357 (2008).
42. Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int. J. Endocrinol. 2010, 906163 (2010).
43. Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J. Intern. Med. 260(2), 177-182 (2006).
44. Reh CM, Hendy GN, Cole DE, Jeandron DD. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J. Clin. Endocrinol. Metab. 96(4), E707-E712 (2011).
45. Lu JY, Yang Y, Gnacadja G, Christopoulos A, Reagan JD. Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3- methoxyphenyl)ethyl)-1- propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J. Pharmacol. Exp. Ther. 331(3), 775-786 (2009).
46. Khan AA, Bilezikian JP, Kung AW et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89(7), 3319-3325 (2004)